Collagen Matrix With and Without Enamel Matrix Derivative

NCT ID: NCT03467802

Last Updated: 2019-07-01

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 30 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-01-01
• Study Completion Date: 2021-12-31

Brief Summary

The purpose of this prospective, double-blinded, randomized, split-mouth study is to compare the effectiveness of a porcine collagen matrix (CM) and coronally advanced flap (CAF) with or without the addition of enamel matrix derivative (EMD) in the treatment of Miller Class I, II, or predictable class III recession defects. One defect will receive CM + CAF + EMD (Experimental), while the other will receive CM + CAF (Control) alone. The treatment of 60 similarly sized Miller class I, II, or predictable class III recession defects on single-rooted teeth in 30 subjects using CM + CAF + EMD or CM + CAF alone will be evaluated. The subjects will be in good health, non-smokers, periodontally healthy with good oral hygiene and have no contraindications to periodontal surgery. Paired, similar sized defects on single-rooted teeth will be in the same subject and measure within 2mm of each other. One defect will be randomly assigned as the test group using CM + CAF + EMD, and the other as the control group using only CM + CAF. Clinical measurements will be made using a UNC-15 periodontal probe by calibrated, board certified periodontists and will include: probing depth (PD), clinical attachment level (CAL), vertical recession (RD), and width of keratinized tissue (KT). Percent root coverage (%RC) will be calculated. The measurements will be used to evaluate surgical outcome. Surgical outcome will also be assessed using stone models. All measurements will be taken at baseline (on the day of the surgery) and 3 and 6 months post-surgery for comparison.

Conditions

Gingival Recession

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Interventions

enamel matrix derivative

Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.

Intervention Type: BIOLOGICAL

Porcine collagen matrix

Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.

Intervention Type: DEVICE

Other Intervention Names

Emdogain®; Mucograft®

Eligibility Criteria

Inclusion Criteria

• Age 18 years or over
• Patient will remain in the Capital region for at least 6 months following the surgical procedure for follow up appointments
• Patient must be otherwise periodontally healthy
• Patient must be systemically healthy (ASA class I or II)
• Patient must have no contraindications to periodontal surgery
• Patient must have demonstrated good oral hygiene (plaque index <1 according to Silness and Löe)
• Paired Miller Class I, II or predictable III recession defects
• Bilateral, facial defects on single-rooted teeth

Exclusion Criteria

• Self-reported history of smoking within previous 6 months
• Does not meet any of the preceding criteria
• Female patients who are pregnant or nursing
• Antibiotic medications taken within the last 6 months
• History of mucogingival surgery at the sites of interest
• Poor plaque control (>25% of sites)
• Those with clinically significant systemic disease, which may affect healing (i.e. uncontrolled diabetes or bone metabolic disease)
• Allergy to chlorhexidine gluconate (Peridex)
• Does not sign study consent or HIPAA forms
• Bleeding complications (e.g. hemophilia)
• Warfarin therapy
• History of osteoporosis or taking bisphosphonate medications
• History of radiation therapy in the head and neck area
• Mobile teeth beyond physiologic mobility
• Facial restorations at the site to be treated
• Recession defects that will require more than one 15x20mm Mucograft (per side)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Walter Reed National Military Medical Center

FED

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Walter Reed NMMC

Bethesda, Maryland, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Ryan A Kaye, DMD

Role: CONTACT

ryan.a.kaye.mil@mail.mil

3012952127

Brent Tibbet, DMD

Role: CONTACT

3013194831

Facility Contacts

Ryan A Kaye, DMD

Role: primary

ryan.a.kaye.mil@mail.mil

301-295-2127

Other Identifiers

WRNMMC-2017-0123

Identifier Type: -

Identifier Source: org_study_id